Richard L Verrier1, Bruce D Nearing2, Bryan Olin3, Paul Boon4, Steven C Schachter5. 1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address: rverrier@bidmc.harvard.edu. 2. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. 3. LivaNova PLC, Houston, TX, United States. 4. On Behalf of the E-36 Study Group, Ghent University Hospital, Ghent, Belgium. 5. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States; Massachusetts General Hospital and Center for Integration of Medicine and Innovative Technology, Boston, MA, United States.
Abstract
OBJECTIVE: Reports of cardiac arrhythmias and cardiac pathology at postmortem examination of patients with epilepsy suggest a possible cardiac component of risk for sudden unexpected death in epilepsy (SUDEP). T-wave alternans (TWA) is an established marker of cardiac electrical instability and risk for sudden death in patients with cardiovascular disease. We determined the TWA level before vagus nerve stimulation (VNS) system implantation and subsequently the effect of VNS on TWA in patients with drug-resistant epilepsy. METHODS: Patients (n=28) from the Seizure Detection and Automatic Magnet Mode Performance Study (E-36), a clinical trial of the AspireSR® VNS Therapy System® (NCT01325623), were monitored with ambulatory electrocardiograms (ECGs) ~2weeks before de novo VNS system implantation and following 2- to 4-week VNS titration during a protocol-specified 3- to 5-day epilepsy monitoring unit stay with concurrent EEG/ECG recordings. The TWA level was assessed interictally by the Modified Moving Average (MMA) method. RESULTS: At preimplantation baseline, TWA was elevated above the 47-μV abnormality cutpoint in 23 (82%) patients with drug-resistant epilepsy. In 16 (70%) patients, TWA level was reduced during VNS treatment to <47μV, thereby converting positive TWA test results to negative. Peak TWA level in all 28 patients improved (group mean, 43%, from 72±4.3 to 41±2.3μV; p<0.0001). Vagus nerve stimulation was not associated with reduced heart rate (77±1.4 to 75±1.4beats/min; p=0.18). Heart rate variability was unchanged. SIGNIFICANCE: These findings suggest significant interictal cardiac electrical instability in this population of patients with drug-resistant epilepsy and suggest that VNS may be a novel approach to reducing risk.
OBJECTIVE: Reports of cardiac arrhythmias and cardiac pathology at postmortem examination of patients with epilepsy suggest a possible cardiac component of risk for sudden unexpected death in epilepsy (SUDEP). T-wave alternans (TWA) is an established marker of cardiac electrical instability and risk for sudden death in patients with cardiovascular disease. We determined the TWA level before vagus nerve stimulation (VNS) system implantation and subsequently the effect of VNS on TWA in patients with drug-resistant epilepsy. METHODS:Patients (n=28) from the Seizure Detection and Automatic Magnet Mode Performance Study (E-36), a clinical trial of the AspireSR® VNS Therapy System® (NCT01325623), were monitored with ambulatory electrocardiograms (ECGs) ~2weeks before de novo VNS system implantation and following 2- to 4-week VNS titration during a protocol-specified 3- to 5-day epilepsy monitoring unit stay with concurrent EEG/ECG recordings. The TWA level was assessed interictally by the Modified Moving Average (MMA) method. RESULTS: At preimplantation baseline, TWA was elevated above the 47-μV abnormality cutpoint in 23 (82%) patients with drug-resistant epilepsy. In 16 (70%) patients, TWA level was reduced during VNS treatment to <47μV, thereby converting positive TWA test results to negative. Peak TWA level in all 28 patients improved (group mean, 43%, from 72±4.3 to 41±2.3μV; p<0.0001). Vagus nerve stimulation was not associated with reduced heart rate (77±1.4 to 75±1.4beats/min; p=0.18). Heart rate variability was unchanged. SIGNIFICANCE: These findings suggest significant interictal cardiac electrical instability in this population of patients with drug-resistant epilepsy and suggest that VNS may be a novel approach to reducing risk.
Authors: Yuan Yuan; Jonathan L Hassel; Anisiia Doytchinova; David Adams; Keith C Wright; Chad Meshberger; Lan S Chen; Maria P Guerra; Changyu Shen; Shien-Fong Lin; Thomas H Everett; Vicenta Salanova; Peng-Sheng Chen Journal: Heart Rhythm Date: 2017-08-01 Impact factor: 6.343
Authors: Francisco G Sanchez-Conde; Eric N Jimenez-Vazquez; David S Auerbach; David K Jones Journal: Front Mol Neurosci Date: 2022-05-03 Impact factor: 6.261
Authors: Morgan B Lee; Daniel R Kramer; Terrance Peng; Michael F Barbaro; Charles Y Liu; Spencer Kellis; Brian Lee Journal: J Clin Neurosci Date: 2019-07-30 Impact factor: 1.961
Authors: Winthrop F Gillis; Charles A Lissandrello; Jun Shen; Ben W Pearre; Alket Mertiri; Felix Deku; Stuart Cogan; Bradley J Holinski; Daniel J Chew; Alice E White; Timothy M Otchy; Timothy J Gardner Journal: J Neural Eng Date: 2018-02 Impact factor: 5.379